Market open
BioCardia Inc./$BCDA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
Ticker
$BCDA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
19
ISIN
US09060U6064
Website
BioCardia Inc. Metrics
BasicAdvanced
$14M
-
-$2.90
1.28
-
Price and volume
Market cap
$14M
Beta
1.28
52-week high
$3.20
52-week low
$1.73
Average daily volume
80K
Financial strength
Current ratio
1.13
Quick ratio
1.022
Long term debt to equity
67.622
Total debt to equity
113.62
Management effectiveness
Return on assets (TTM)
-149.03%
Return on equity (TTM)
2,074.67%
Valuation
Price to revenue (TTM)
129.624
Price to book
15.06
Price to tangible book (TTM)
15.06
Price to free cash flow (TTM)
-0.936
Growth
Revenue change (TTM)
-87.84%
Earnings per share change (TTM)
-64.66%
3-year revenue growth (CAGR)
-61.48%
3-year earnings per share growth (CAGR)
-36.28%
BioCardia Inc. News
AllArticlesVideos
BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025
GlobeNewsWire·5 days ago
Insider Buying Surges in May. Especially These 5 Stocks
24/7 Wall Street·1 week ago
BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for BioCardia Inc. stock?
BioCardia Inc. (BCDA) has a market cap of $14M as of May 14, 2025.
What is the P/E ratio for BioCardia Inc. stock?
The price to earnings (P/E) ratio for BioCardia Inc. (BCDA) stock is 0 as of May 14, 2025.
Does BioCardia Inc. stock pay dividends?
No, BioCardia Inc. (BCDA) stock does not pay dividends to its shareholders as of May 14, 2025.
When is the next BioCardia Inc. dividend payment date?
BioCardia Inc. (BCDA) stock does not pay dividends to its shareholders.
What is the beta indicator for BioCardia Inc.?
BioCardia Inc. (BCDA) has a beta rating of 1.28. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.